경계성 절제 가능 및 국소 진행성 췌장암에서 PD-L1 항체와 결합된 AG 및 FOLFIRINOX 순차 치료의 전환 치료 임상시험¶

AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.

안내

이 페이지는 자동 수집·AI 요약된 정보입니다. 의료 조언이 아니며, 치료 결정은 반드시 담당 의료진과 상의하세요. 응급 상황은 응급 가이드 또는 119.

항목	내용
등록번호	NCT07208539
상태	모집 예정
단계	2상
시험 약물/중재	Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1
대상 질환	Pancreatic Cancer
스폰서	Shanghai Zhongshan Hospital
연령·성별	18 Years ~ 제한 없음 · ALL
목표 인원	77
시작 / 1차 완료 예정	2025-10-10 / 2026-04-09
국내 실시기관	없음
실시 국가	0개국, 기관 0곳
결과 게시	아니오
최근 갱신	2025-10-06

문의처 (등록된 중앙 연락처)¶

Wenquan Wang +86 21 31587861 wang.wenquan@zs-hospital.sh.cn

국내 기관 참여 문의는 해당 병원 임상시험센터 또는 담당 주치의를 통해 하세요. 참여 방법 안내

시험 개요¶

이 임상시험은 경계성 절제 가능(borderline resectable) 및 국소 진행성(locally advanced) 췌장암 환자를 대상으로 합니다. 알부민 팩리탁셀(albumin paclitaxel), 젬시타빈(gemcitabine) 및 PD-L1 항체 병용 요법 후 리포조말 이리노테칸(liposomal irinotecan), 옥살리플라틴(oxaliplatin), 5-FU/LV 및 PD-L1 항체 병용 요법을 순차적으로 시행합니다. 초록에 명시된 주요 질문은 이 순차 치료가 절제율을 높이는지, 그리고 효과적이고 안전한 치료법인지 확인하는 것입니다. 총 77명의 환자가 참여할 예정이며 2상 임상시험으로 진행됩니다.

대상 질환은 경계성 절제 가능 및 국소 진행성 췌장암입니다.
치료법은 AG 및 PD-L1 항체 치료 후 FOLFIRINOX 및 PD-L1 항체 치료를 순차적으로 진행하는 것입니다.
목표 환자 수는 77명이며, 초록에 명시된 생존기간이나 반응률 등의 수치 결과는 아직 없습니다.

참여 조건 (AI 정리, 원문 확인 필요)¶

선정 기준: - 만 18세 이상, 성별 무관 - NCCN 가이드라인(2024.V2)에 따른 경계성 절제 가능 또는 국소 진행성 췌장암 환자 - 이전 항암 치료(방사선, 절제, 화학요법, 표적치료, 면역치료 등)를 받지 않은 환자 - RECIST v1.1 기준에 따른 측정 가능한 병변이 최소 1개 이상 있는 환자 - ECOG 수행 능력 평가 0~1 - 예상 생존기간 3개월 이상 - 주요 장기 기능이 기준을 충족하는 환자 - 가임기 여성의 경우 첫 투여 3일 전 혈액 임신 테스트 결과가 음성이고 피임에 동의한 환자 - 자발적으로 연구에 참여하고 동의서에 서명한 환자

제외 기준: - 췌장관 상피세포 이외의 기원인 췌장암 환자 (신경내분비암, 선방세포암, 모세포종, 고형 가유두상 종양 등) - 중추신경계 전이가 알려진 환자 - 심각한 위장관 기능 장애가 있는 환자 - 안정화되지 않은 제3공간 삼출액(흉수 등)이 있는 환자 - 임상 증상이 있어 천자 및 배액이 필요한 복수가 있는 환자 - 간질성 폐렴 또는 간질성 폐질환 병력이 있거나 현재 동반된 환자 - 활동성 자가면역질환이 있거나 재발 이력이 있는 환자

선정/제외 기준 원문 (영어)

Inclusion Criteria:

Age ≥ 18 years old, gender not restricted
According to the NCCN Clinical Practice Guidelines for Pancreatic Cancer (2024.V2 version), patients with borderline resectable/locally advanced pancreatic cancer as evaluated by multidisciplinary and imaging assessment, the definition of borderline resectability includes:
No distant metastasis;
Arteries: 1. Pancreatic head/neck: The tumor is in contact with the common hepatic artery and does not extend to the abdominal aorta or the hepatic artery bifurcation, and can be safely resected and reconstructed; the tumor is in contact with the superior mesenteric artery ≤ 180°; the tumor contacts variant arteries (such as the accessory right hepatic artery, replacement of the hepatic right artery, replacement of the common hepatic artery or the starting part of the accessory/secondary artery, etc.), but can be safely resected and reconstructed. 2. Pancreatic body/tail: The tumor is in contact with the abdominal aorta ≤ 180°;
Veins: The tumor is in contact with the superior mesenteric vein or portal vein > 180°, or contact ≤ 180° combined with irregular venous contour or venous thrombosis, and there are appropriate blood vessels at the proximal and distal ends of the affected area that can be completely resected and reconstructed; the tumor contacts the inferior vena cava;

Local advanced pancreatic cancer is defined as:

No distant metastasis;
Arteries: 1. Pancreatic head/neck: The tumor is in contact with the superior mesenteric artery or the celiac trunk artery > 180°; 2. Pancreatic body/tail: The tumor is in contact with the superior mesenteric artery or the celiac trunk artery > 180°; the tumor contacts the celiac trunk artery and invades the abdominal aorta;
Veins: Due to tumor invasion, vein occlusion or involvement of a large area of the superior mesenteric vein and ileal branch, it is impossible to safely reconstruct the portal vein - superior mesenteric vein;
No previous anti-tumor treatment (including radiotherapy, ablation, chemotherapy, targeted therapy, immunotherapy, etc.), investigational drug treatment;
Must have at least one measurable lesion as the target lesion (according to RECIST v1.1 standard);
ECOG: 0 - 1
Expected survival ≥ 3 months;
Good function of major organs, that is, in accordance with the following standards (within 14 days before randomization, no blood components, cell growth factors were received):
Neutrophils ≥ 1.5 * 10\^9/L; platelets ≥ 80 * 10\^9/L; hemoglobin ≥ 9 g/dl; serum albumin ≥ 3 g/dl;
Total bilirubin ≤ 1.5 times the upper limit of normal (biliary obstruction allows biliary drainage); ALT and AST ≤ 3 times the upper limit of normal;
Serum creatinine ≤ 1.5 times the upper limit of normal, creatinine clearance rate ≥ 60 ml/min;
INR ≤ 1.5 times the upper limit of normal and APTT ≤ 1.5 times the upper limit of normal (for those using stable doses of anticoagulation therapy such as low molecular weight heparin or warfarin and INR within the expected treatment range of the anticoagulant can be screened);
Electrocardiogram: QTcF ≤ 450 ms (male), ≤ 470 ms (female);
Cardiac echocardiography: LVEF (left ventricular ejection fraction) ≥ 50%;
Female participants with reproductive capacity must undergo a blood pregnancy test 3 days before the first administration, and the result must be negative, not in lactation period, and willing to take effective contraceptive methods during the trial and within 2 months after the last administration of ademetelstat or 9 months after chemotherapy drugs (whichever is longer) (for male participants whose partners have reproductive capacity, surgical sterilization should be performed, or agree to take effective contraceptive methods within 2 months after the last administration of ademetelstat or 6 months after chemotherapy drugs, during the study period, sperm donation is not allowed).
Participants voluntarily join this study and sign the informed consent form.

Exclusion Criteria:

Pancreatic cancer originating from non-pancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, pancreatic acinar cell carcinoma, pancreatic blastoma, solid-pseudopapillary tumors patients
Patients with known central nervous system metastasis
Severe gastrointestinal dysfunction (with bleeding, obstruction; grade 2 or higher inflammation; grade 1 or higher diarrhea)
Randomly within the previous 2 weeks, there was third-space effusion (such as large pleural effusion) that could not reach a stable state (after removing the drainage tube, no intervention treatment was required)
Abdominal effusion with clinical symptoms, requiring puncture and drainage, or patients who had undergone abdominal effusion drainage within 3 months previously (excluding those with only imaging showing a small amount of abdominal effusion and controllable, but without clinical symptoms)
Currently accompanied by interstitial pneumonia or interstitial lung disease, or having a history of interstitial pneumonia or interstitial lung disease requiring hormone treatment previously, or other possible pulmonary fibrosis, organizing pneumonia (such as obliterative bronchiolitis), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia or in the screening period, chest CT showing active pneumonia or severely impaired lung function subjects; active tuberculosis
Presence of active autoimmune disease or having a history of autoimmune disease that may recur [including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism (only subjects with controlled hormone replacement therapy can be enrolled)], having a skin disease that does not require systemic treatment such as vitiligo, psoriasis, alopecia, receiving insulin treatment for controlled type 1 diabetes or having completely resolved childhood asthma and no need for any intervention after adulthood, eligible for enrollment
Known peripheral neuropathy (CTCAE ≥ 3 grade)
Known dihydroorotate dehydrogenase (low activity) or deficiency
Randomly within the previous 2 weeks, had severe infection (CTCAE > 2 grade), such as severe pneumonia requiring hospitalization, sepsis, infection complications, etc.; randomly within the previous 2 weeks, had symptoms and signs of infection requiring intravenous antibiotic treatment (except for prophylactic use of antibiotics)
Had received any of the following treatments:
Randomly within the previous 2 weeks, the medication used included strong inhibitors/inducers of CYP3A4, CYP2C8 or strong inhibitors of UGT1A1;
Randomly within the previous 2 weeks, received immunosuppressants or systemic hormone treatment to achieve immunosuppression purposes (dose > 10mg/day prednisone or other equivalent efficacy hormones);
Randomly within the previous 2 weeks, received radiotherapy;
Randomly within the previous 4 weeks, underwent major surgery (such as thoracotomy, laparotomy, etc.);
Randomly within the previous 4 weeks, received any other clinical research drug treatment, unless it is an observational (non-interventional) clinical study or follow-up of an interventional clinical study.
Abnormal coagulation function, with bleeding tendency or undergoing thrombolysis or anticoagulation treatment. Allowed to use preventive low-dose aspirin (≤100mg/day) or low-molecular-weight heparin (enoxaparin 40mg/day and other low-molecular-weight heparins at equivalent doses)
Had poor control of clinical symptoms or diseases of the heart, such as: (1) NYHA grade 2 or above heart failure; (2) unstable angina pectoris; (3) having had a myocardial infarction within 6 months; (4) having clinical significance of supraventricular or ventricular arrhythmias and requiring treatment or intervention
Randomly within the previous 5 years had malignant tumors other than pancreatic cancer, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin
Those who are known to be allergic to PD-L1, gemcitabine, albumin paclitaxel, gemcitabine, albumin paclitaxel, irinotecan liposome, other liposome products, oxaliplatin, 5-FU, folic acid calcium, or any of the components in the above products
Those who are known to have acquired immunodeficiency syndrome (AIDS) or have tested positive for HIV, or active syphilis patients
Those who have a clear history of neurological or mental disorders, including epilepsy or dementia
Based on the investigator's judgment, the subjects have other factors that may cause them to be forced to terminate the study prematurely, such as non-compliance with the protocol, having other serious diseases (including mental disorders) that require combined treatment, having severely abnormal laboratory test values with clinical significance, family or social factors, and situations that may affect the safety of the subjects or the collection of trial data.

출처: ClinicalTrials.gov · 수집 2026-10-06 · 갱신 2026-10-06

댓글 기능은 아직 설정 전입니다 (관리자: docs/SETUP.md의 giscus 항목 참고). 의견은 GitHub Discussions에 남겨 주세요.